% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Leypoldt:302808,
      author       = {L. B. Leypoldt and L. Guo and B. Besemer and M. Hänel and
                      M.-S. Raab and C. Mann and C. S. Michel and H. C.
                      Reinhardt$^*$ and I. W. Blau and M. Görner and Y.-D. Ko and
                      M. de Wit and H. Salwender and C. Scheid and U. Graeven and
                      R. Peceny and P. Staib and A. Dieing and H. Goldschmidt and
                      C. Bokemeyer and T. Zeller and D. Westermann and K. C.
                      Weisel and R. Twerenbold and A. Beitzen-Heineke},
      title        = {{C}ardiac biomarkers for risk stratification in newly
                      diagnosed high-risk multiple myeloma in the {GMMG}-{CONCEPT}
                      trial.},
      journal      = {Cardio-Oncology},
      volume       = {11},
      number       = {1},
      issn         = {2057-3804},
      address      = {[London]},
      publisher    = {BioMed Central},
      reportid     = {DKFZ-2025-01348},
      pages        = {63},
      year         = {2025},
      abstract     = {Cardiovascular adverse events (CVAE) are clinically
                      relevant side effects during treatment with the proteasome
                      inhibitor carfilzomib. We investigated the predictive value
                      of cardiac biomarkers for onset of CVAE in patients with
                      newly diagnosed high-risk multiple myeloma treated with
                      isatuximab, carfilzomib, lenalidomide, and dexamethasone in
                      the GMMG-CONCEPT study (NCT03104842). Patients included in
                      this prospective, multicenter correlative study were
                      eligible if a serum sample before treatment initiation and
                      at ≥ 1 later study time point were available. N-terminal
                      pro-b-type natriuretic peptide (NT-proBNP) and
                      high-sensitive Troponin I (hsTropI) were measured using
                      immunoassays. Time-to-event analyses were performed using
                      Kaplan-Meier estimators and log-rank test was used for
                      statistical analysis. Among 126 patients included in this
                      study, 40 reported incident CVAE. No significant differences
                      were observed for age, sex, cardiovascular risk factors and
                      cardiovascular comorbidities between patients who
                      experienced CVAE compared to patients without CVAE.
                      NT-proBNP levels were elevated at baseline in 96 $(76\%)$
                      patients. Neither baseline levels nor change in NT-proBNP
                      level during early induction cycles were predictive for the
                      occurrence of CVAE. In contrast, elevation of hsTropI above
                      the 99th percentile was rare. Patients with hsTropI level
                      ≥ 2.9 ng/L, corresponding to the lower limit of
                      quantification, showed a higher risk for CVAE compared to
                      patients with hsTropI < 2.9 ng/L at baseline (p = 0.0023).
                      In conclusion, in patients with newly diagnosed high-risk
                      multiple myeloma undergoing carfilzomib-based quadruplet
                      treatment, low hsTropI pretreatment levels are of high
                      negative predictive value for the occurrence of CVAE whereas
                      elevated NT-proBNP levels are very common before treatment
                      initiation.},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40611354},
      pmc          = {pmc:PMC12224601},
      doi          = {10.1186/s40959-025-00358-x},
      url          = {https://inrepo02.dkfz.de/record/302808},
}